Scarica l'app Stockscreener
174.84
4.98%
8.29
Dopo l'orario di chiusura:
174.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$166.55
Aprire:
$168.3
Volume 24 ore:
19.06M
Relative Volume:
6.63
Capitalizzazione di mercato:
$37.29B
Reddito:
$447.02M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-28.29
EPS:
-6.1812
Flusso di cassa netto:
$-906.14M
1 W Prestazione:
-11.25%
1M Prestazione:
-14.11%
6M Prestazione:
+75.79%
1 anno Prestazione:
+151.89%
Intervallo 1D:
$166.71
$178.21
Intervallo di 1 settimana:
$161.02
$205.23
Portata 52W:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Confronta INSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?ARM Holdings (NASDAQ:ARM), BitMine Immersion (AMEX:BMNR), Insmed (NASDAQ:INSM), Lennar (NYSE:LEN) - Benzinga
INSM stock plummets on sinus study failure, adds new pipeline asset - MSN
Voya Investment Management LLC Sells 187,840 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed (BIT:1INSM) Price Target Increased by 16.99% to 218.23 - Nasdaq
The 'worst-case scenario' — why Insmed just reversed after a 181% six-month sprint - MSN
Will Insmed Incorporated (IM8N) stock announce a stock splitPortfolio Performance Summary & Accurate Intraday Trading Signals - ulpravda.ru
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
What risks investors should watch in Insmed Incorporated stockWeekly Risk Summary & Stock Portfolio Risk Control - ulpravda.ru
Why Insmed Incorporated stock is considered a top pick2025 Bull vs Bear & Detailed Earnings Play Strategies - Улправда
Brinsupri setback slices Insmed market cap — Clinical Report - BioCentury
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
Insmed Insider Sold Shares Worth $1,786,457, According to a Recent SEC Filing - marketscreener.com
INSMED Chair and CEO William Lewis Sells 10,699 Shares - TradingView — Track All Markets
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next - ts2.tech
Insmed (MIL:1INSM) EV-to-FCF : -35.92 (As of Dec. 19, 2025) - GuruFocus
Insmed (MIL:1INSM) EV-to-OCF : -36.87 (As of Dec. 19, 2025) - GuruFocus
Will Insmed Incorporated (IM8N) stock test record highs in 2025July 2025 Macro Moves & Scalable Portfolio Growth Methods - DonanımHaber
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study - BioSpace
Goldman Sachs reiterates Buy rating on Insmed stock despite trial setback - Investing.com
FY2028 Earnings Estimate for Insmed Issued By HC Wainwright - MarketBeat
Is Insmed Incorporated stock a good choice for value investorsJuly 2025 Fed Impact & AI Enhanced Trading Signals - DonanımHaber
How Insmed Incorporated (IM8N) stock correlates with oil marketsBond Market & Real-Time Volume Analysis Alerts - Улправда
Truist Securities assumes coverage on Insmed stock with Buy rating By Investing.com - Investing.com Canada
Truist Securities assumes coverage on Insmed stock with Buy rating - Investing.com
How Insmed Incorporated stock performs in high volatility markets2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
Insmed Inc : Truist Securities Assumes Covera - 富途牛牛
Will Insmed Incorporated stock remain a Wall Street favoriteJuly 2025 Reactions & Weekly High Conviction Trade Ideas - Улправда
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset - sharewise.com
Insmed stock price target lowered to $212 by Mizuho after negative study data - Investing.com Australia
RBC Capital Maintains Insmed (INSM) Outperform Recommendation - Nasdaq
HC Wainwright & Co. Maintains Insmed (INSM) Buy Recommendation - Nasdaq
Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news - CNBC
Chmn Lewis Files To Sell 10,699 Of Insmed Inc [INSM] - TradingView — Track All Markets
Biotech, Up 181%, Faces Its 'Worst-Case Scenario' And Dives - Investor's Business Daily
Insmed stock price target lowered to $195 at Leerink on failed trial By Investing.com - Investing.com South Africa
Insmed price target lowered to $203 from $214 at BofA - TipRanks
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts - ts2.tech
Micron, Insmed among market cap stock movers on Thursday By Investing.com - Investing.com UK
Medical Stocks Worth WatchingDecember 18th - MarketBeat
Micron, Insmed among market cap stock movers on Thursday - Investing.com India
Insmed Stock (INSM) Sinks 18% as Analysts Cut Targets after Trial Failure - TipRanks
INSM: TD Cowen Adjusts Insmed's Price Target Amid Buy Rating | I - GuruFocus
Is Insmed’s 183.7% 2025 Surge Justified by Its Long Term Growth Outlook? - simplywall.st
INSM: Goldman Sachs Lowers Price Target to $225, Maintains Buy R - GuruFocus
Insmed (NASDAQ:INSM) Given New $241.00 Price Target at TD Cowen - MarketBeat
Insmed (INSM) Stock Drops Significantly Amid Market Fluctuations - GuruFocus
INSM: HC Wainwright & Co. Adjusts Price Target, Maintains Buy Ra - GuruFocus
Why Is Insmed Stock Falling Thursday? - Benzinga
Insmed is Now Oversold (INSM) - Nasdaq
Insmed's Pipeline Can Deliver Potential Gains Despite Brensocatib Setback, RBC Says - marketscreener.com
After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset - Endpoints News
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Dec 18 '25 |
Sale |
166.97 |
10,699 |
1,786,457 |
303,911 |
2.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):